LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Baxter International Inc

Geschlossen

BrancheGesundheitswesen

19.17 0.58

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

19.02

Max

19.65

Schlüsselkennzahlen

By Trading Economics

Einkommen

1B

-15M

Verkäufe

-273M

2.7B

KGV

Branchendurchschnitt

86.308

49.701

EPS

0.36

Dividendenrendite

2.08

Gewinnspanne

-0.555

Angestellte

37,500

EBITDA

750M

303M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+11.09% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.08%

2.39%

Nächstes Ergebnis

30. Juli 2026

Nächste Dividendenausschüttung

1. Juli 2026

Nächstes Ex-Dividendendatum

29. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-358M

9.2B

Vorheriger Eröffnungskurs

18.59

Vorheriger Schlusskurs

19.17

Nachrichtenstimmung

By Acuity

27%

73%

148 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Baxter International Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Feb. 2026, 20:10 UTC

Ergebnisse

Baxter Is One of the S&P 500's Worst Performers Today. Earnings Were Brutal. -- Barrons.com

12. Feb. 2026, 14:43 UTC

Ergebnisse

Baxter Is One of the S&P 500's Worst Performers Today. Earnings Were Brutal. -- Barrons.com

Peer-Vergleich

Kursveränderung

Baxter International Inc Prognose

Kursziel

By TipRanks

11.09% Vorteil

12-Monats-Prognose

Durchschnitt 21.14 USD  11.09%

Hoch 27 USD

Tief 17 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Baxter International Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

8 ratings

2

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

30.475 / 31.345Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

148 / 345 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Baxter International Inc

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
help-icon Live chat